FDA Approved: QINLOCK — Supplemental Application (Deciphera Pharmaceuticals, LLC)

View source ↗

Summary

The FDA approved a supplemental application for QINLOCK (ripretinib) submitted by Deciphera Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• QINLOCK (ripretinib)

Snippet

SUPPL AP for QINLOCK (RIPRETINIB)